Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016
Summary
Global Markets Directs, Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016, provides in depth analysis on Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics.
The report provides comprehensive information on the Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
- The report reviews Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) Overview 7
Therapeutics Development 8
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Stage of Development 8
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Therapy Area 9
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Indication 10
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Companies 13
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development 20
Ablynx NV 20
Amgen Inc. 21
Apogenix GmbH 22
Bristol-Myers Squibb Company 23
Five Prime Therapeutics, Inc. 24
Incyte Corporation 25
MedImmune, LLC 26
Merck & Co., Inc. 27
Novartis AG 28
OncoMed Pharmaceuticals, Inc. 29
Regeneron Pharmaceuticals, Inc. 30
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles 31
AMG-228 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
BMS-986156 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
FPA-154 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
GWN-323 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
INCAGN-1876 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
LKZ-145 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
MEDI-1873 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
MK-1248 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MK-4166 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Monoclonal Antibodies to Agonize GITR for Immunology and Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Monoclonal Antibody to Agonize GITR for Hematological Malignacies and Solid Tumors - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Monoclonal Antibody to Agonize GITR for Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Recombinant Protein to Agonize GITR for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Recombinant Protein to Agonize GITR for Solid Tumor - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TRX-518 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Featured News & Press Releases 48
Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting 48
Apr 19, 2016: OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016 48
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 49
Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody 50
Sep 16, 2015: OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference 50
Apr 05, 2011: Tolerx Presents Preclinical Data On New Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses 51
Feb 09, 2011: Tolerx Presents Preclinical Data On TRX518 52
Dec 14, 2010: Tolerx Initiates Phase I Clinical Trial Of TRX518 For Treatment Of Cancer 53
Dec 01, 2010: Tolerx And Cancer Research Institute Enter Collaboration To Accelerate Development Of TRX518 54
Jun 25, 2010: Tolerx Reports Preclinical Data On TRX518 For Treatment Of Cancer 54
Oct 21, 2008: Laureate To Manufacture Tolerxs TRX518 Antibody 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57
List Of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 17
Number of Products by Stage and Molecule Type, H1 2016 19
Pipeline by Ablynx NV, H1 2016 20
Pipeline by Amgen Inc., H1 2016 21
Pipeline by Apogenix GmbH, H1 2016 22
Pipeline by Bristol-Myers Squibb Company, H1 2016 23
Pipeline by Five Prime Therapeutics, Inc., H1 2016 24
Pipeline by Incyte Corporation, H1 2016 25
Pipeline by MedImmune, LLC, H1 2016 26
Pipeline by Merck & Co., Inc., H1 2016 27
Pipeline by Novartis AG, H1 2016 28
Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 29
Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 30
List Of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Actions, H1 2016 16
Number of Products by Molecule Types, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 18
